JNK inhibition suppresses microglial NLRP3 activation and oxidative stress but unexpectedly worsens pain in diabetic neuropathy: insights from a combined in vitro and in vivo pharmacological study
Neurochem Int. 2026 May 4:106167. doi: 10.1016/j.neuint.2026.106167. Online ahead of print.ABSTRACTDiabetic neuropathy (DN) is driven by neuroinflammation and oxidative stress, with c-Jun N-terminal kinase (JNK) as a key mediator; however, the effects of JNK inhibition on neuropathic pain remain unclear. Therefore, we investigated the therapeutic potential of the JNK inhibitor SP600125 in a type 2
May 7, 2026